Abstract
Stereotactic body radiation therapy (SBRT) is a precision treatment that allows high doses of radiation to be administered to the tumor volume while limiting the dose received by the surrounding healthy organs. This makes it possible to administer ablative doses to the tumor with high local control, making it an alternative in the treatment of hepatocellular carcinoma. This treatment is indicated in patients as a bridge to transplant, inoperable, or complementary treatment to other therapies such as embolization, with local control above 90% according to series. Doses and fractions are variable, and the optimal scheme has not been established. The use of this therapy has increased in recent years, although its evidence is limited. Prospective randomized studies are necessary to make this treatment the first line of action.
Reference56 articles.
1. Gunderson and Tepper. Clinical Radiation Oncology. 4th ed. Philadelphia: Elsevier; 2016
2. Potters L, Kavanagh B, Galvin JM, et al. American society for therapeutic radiology and oncology (ASTRO) and American college of radiology (ACR) practice guideline for the performance of stereotactic body radiation therapy. International Journal of Radiation Oncology, Biology, Physics. 2010;76(2):326-332
3. Benedict SH, Yenice KM, Followill D, et al. Stereotactic body radiation therapy: The report of AAPM task group 101. Medical Physics. 2010;37(8):4078-4101
4. Fernández-Letón P, Baños C, Bea J, Delgado Rodríguez JM, De Blas PR, Martínez Ortega J, et al. Recomendaciones de la Sociedad Española de Física Médica (SEFM) sobre implementación y uso clínico de radioterapia estereotáxica extracraneal (SBRT). SEFM Revised Fisihery Medical. 2017;18(2):1-11
5. Lasley FD, Mannina EM, Johnson CS. Treatment variables related to liver toxicity in patients with hepatocellular carcinoma, Child-Pugh class A and B enrolled in a phase 1-2 trial of stereotactic body radiation therapy. Practical Radiation Oncology. 2015;5(5):e443-e449